US Stock Movements: Trevi Therapeutics surges on October 20 due to CORAL data and chronic cough medication

Trevi Therapeutics October 20th Surge Interpretation

Keywords: CORAL data, chronic cough medication

1. On October 20th, Trevi delivered an oral presentation on CORAL phase IIb patient-reported outcomes at the CHEST 2026 conference; according to related materials, patient-reported outcomes in IPF-related chronic cough showed early and sustained improvement during the trial.

2. According to a report on October 20th, Morgan Stanley recently initiated coverage of eight biotechnology companies for the first time and mentioned Trevi’s market opportunity in the chronic cough field; the company is developing the oral extended-release nalfurafine, Haduvio, for various types of chronic cough.

(Disclaimer: This content is generated by AI technology gathering and summarizing publicly available information, for reference only and does not constitute investment advice.)